What kind of drug is Tarceva?
Erlotinib is a type of targeted cancer drug, and is also known by its brand name Tarceva (pronounced tar-see-vah). It is a treatment for: non small cell lung cancer (NSCLC) that has spread (advanced) advanced pancreatic cancer – alongside the chemotherapy drug gemcitabine.
What class drug is erlotinib?
Erlotinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply.
What category of targeted therapy is Tarceva?
Tarceva is a targeted therapy. Tarceva is classified as an epidermal growth factor receptor (EGFR) inhibitor – protein-tyrosine kinase inhibitor (for more detail, see “How Tarceva Works,” below.)
Is Tarceva a chemotherapy drug?
Erlotinib (Tarceva) Erlotinib is a non-chemotherapy drug for the treatment of advanced or metastatic NSCLC and is administered orally once a day. It successfully inhibits EGFR, a protein involved in the growth and development of cancers.
What is the generic name for Tarceva?
Generic Name: erlotinib Erlotinib is used to treat lung and pancreatic cancer. It works by slowing or stopping the growth of cancer cells.
Is erlotinib a cytotoxic drug?
Pretreatment with erlotinib exerted the least profound cytotoxic effect, whereas the administration of cytotoxic drugs followed by erlotinib exhibited the most potent cytotoxic effects.
What is Tarceva approved for?
Tarceva is prescribed for patients with metastatic non-small cell lung cancer (NSCLC) whose cancer has been identified to have certain Epidermal Growth Factor Receptor (EGFR) mutations by an FDA-approved test (first-line treatment).
How effective is Tarceva?
The overall anti-cancer response rate was 9% for patients treated with Tarceva™ and the average duration of response was nearly 8 months. Disease stabilization was achieved in 35% of patients treated with Tarceva™ and progression of cancer occurred in 38% of patients treated with Tarceva™.
What is a third generation TKI?
Third generation TKIs These include osimertinib, EGF816, olmutinib, PF-06747775, YH5448, avitinib and rociletinib. The defining characteristic of these third generation agents is that they have significantly greater activity in EGFR mutant cells than in EGFR WT cells, making them mutant-selective [14].
What is a first generation TKI?
First-generation EGFR TKIs (gefitinib, erlotinib and icotinib) reversibly bind to EGFR and inhibit the binding of ATP to the TK domain. This block hampers cell proliferation, ultimately leading to cell death (11).
Which of the following is a first generation TKI?
What is a second-generation TKI?
Second-generation tyrosine kinase inhibitors (TKIs) are more potent drugs and have expanded inhibition against a broad spectrum of mutations resistant to imatinib. Both nilotinib and dasatinib have demonstrated in vitro and in vivo clinical activity against different types of mutations and various forms of resistance.
Is Tarceva a registered trademark?
Tarceva ® is a registered trademark of OSI Pharmaceuticals, LLC. Other trademarks listed belong to their respective owners. ©2016 Astellas Pharma US, Inc., and Genentech, Inc. All rights reserved.
What is the safety evaluation of Tarceva?
Safety evaluation of TARCEVA is based on 856 cancer patients who received TARCEVA as monotherapy, 308 patients who received TARCEVA 100 or 150 mg plus gemcitabine, and 1228 patients who received TARCEVA concurrently with other chemotherapies.
What is Tarceva (erlotinib)?
Tarceva (erlotinib), a kinase inhibitor, is a quinazolinamine with the chemical name N- (3-ethynylphenyl)-6,7-bis (2-methoxyethoxy)-4-quinazolinamine. Tarceva contains erlotinib as the hydrochloride salt that has the following structural formula:
How should I take Tarceva?
Follow all directions on your prescription label. Your doctor may occasionally change your dose to make sure you get the best results. Do not take this medicine in larger or smaller amounts or for longer than recommended. Take Tarceva on an empty stomach, at least 1 hour before or 2 hours after eating.